KalVista Pharmaceuticals Inc (NASDAQ: KALV) is -17.63% lower on its value in year-to-date trading and has touched a low of $7.39 and a high of $16.88 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KALV stock was last observed hovering at around $9.98 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $10.09, the stock is -2.13% and -8.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.16 million and changing 1.10% at the moment leaves the stock -16.23% off its SMA200. KALV registered 20.69% gain for a year compared to 6-month gain of -10.31%. The firm has a 50-day simple moving average (SMA 50) of $10.9939 and a 200-day simple moving average (SMA200) of $12.068275.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.42% loss in the last 1 month and extending the period to 3 months gives it a -22.38%, and is 12.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.77% over the week and 7.12% over the month.
KalVista Pharmaceuticals Inc (KALV) has around 150 employees, a market worth around $491.54M and $0.00M in sales. Distance from 52-week low is 36.54% and -40.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.74%).
KalVista Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -0.91.The EPS is expected to grow by 10.71% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
175.0 institutions hold shares in KalVista Pharmaceuticals Inc (KALV), with institutional investors hold 111.77% of the company’s shares. The shares outstanding are 42.52M, and float is at 32.34M with Short Float at 22.79%. Institutions hold 110.26% of the Float.
The top institutional shareholder in the company is VR ADVISER, LLC with over 6.25 million shares valued at $73.62 million. The investor’s holdings represent 14.3373 of the KALV Shares outstanding. As of 2024-06-30, the second largest holder is TANG CAPITAL MANAGEMENT LLC with 4.22 million shares valued at $49.7 million to account for 9.6783 of the shares outstanding. The other top investors are SUVRETTA CAPITAL MANAGEMENT, LLC which holds 4.19 million shares representing 9.6168 and valued at over $49.38 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 8.4602 of the shares totaling 3.69 million with a market value of $43.44 million.
KalVista Pharmaceuticals Inc (KALV) Insider Activity
The most recent transaction is an insider sale by Audhya Paul K., the company’s CHIEF MEDICAL OFFICER. SEC filings show that Audhya Paul K. sold 2,187 shares of the company’s common stock on Nov 26 ’24 at a price of $9.87 per share for a total of $21586.0. Following the sale, the insider now owns 97012.0 shares.
KalVista Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 26 ’24 that Yea Christopher (CHIEF DEVELOPMENT OFFICER) sold a total of 1,963 shares of the company’s common stock. The trade occurred on Nov 26 ’24 and was made at $9.87 per share for $19378.0. Following the transaction, the insider now directly holds 91142.0 shares of the KALV stock.
Still, SEC filings show that on Nov 18 ’24, Palleiko Benjamin L (CHIEF EXECUTIVE OFFICER) disposed off 14,400 shares at an average price of $9.26 for $0.13 million. The insider now directly holds 266,598 shares of KalVista Pharmaceuticals Inc (KALV).
